摘要:
Disclosed is a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of pains and pyrexia, hypertension, hypotension, hyperlipemia, inflammatory diseases or diseases due to the functional accentuation of thrombocytes of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutical acceptable carrier or diluent therefor.
摘要:
Disclosed is a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of pains and pyrexia, hypertension, hypotension, hyperlipemia, inflammatory diseases or diseases due to the functional accentuation of thrombocytes of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutical acceptable carrier or diluent therefor.
摘要:
Disclosed herein is a method for preventing senescence and increasing bone mass namely, bone volume and bone strength which method comprises administering 24,25-dihydroxy cholecalciferol in a pharmaceutically effective amount, and also use of 24,25-dihydroxy cholecalciferol for preparing anti-senescent compositions and compositions for increasing bone mass.
摘要:
Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretic activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.
摘要:
Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.
摘要:
Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-L-rhamonoside or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要:
Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.
摘要:
Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.
摘要:
Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-D-xyloside or a pharmaceutically a acceptable salt thereof as an active ingredient.
摘要:
A pharmaceutical composition for regulating prostagrandins, which comprises (a) a derivative of aminobenzoic acid, represented by the following general formula: ##STR1## wherein R.sup.1 denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha)-or 1(beta) position from arabinose, xylose, rhamnose, glucose, galactose, mannose and fructose, and R.sup.2 is a hydrogen atom, an alkyl group of one to four carbon atoms or a pharmaceutically acceptable metal, and (b) a pharmaceutically acceptable carrier or diluent of (a) is disclosed.